Apnimed Inc (APMD) FinancialsAPMDApnimed Inc

Evaluating the bottom line, Apnimed Inc maintains a gross margin of 97.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 80.23%, while the net margin is 82.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively APMD converts its operational activities into shareholder value.

In the context of the broader market, APMD competes directly with industry leaders such as SANA and ODTX. With a market capitalization of $1.18B, it holds a leading position in the sector. When comparing efficiency, APMD's gross margin of 97.45% stands against SANA's N/A and ODTX's N/A. Such benchmarking helps identify whether Apnimed Inc is trading at a premium or discount relative to its financial performance.

The company has a P/E ratio of 27.41 and a price-to-sales ratio of 9.52, indicating a premium valuation relative to its sales. The forward P/E is currently at 0, suggesting that future earnings expectations are uncertain until the FDA decision.